|
||
Eritrocin Pregnancy |
||
Eritrocin crosses the placenta in small amounts. In one study of 11 patients who had detectable Eritrocin levels in the serum, 4 infants did not have detectable cord concentrations. The cord concentrations in the remaining 7 infants generally ranged from 1% to 6% of that found in maternal serum. A case of left absence-of-tibia syndrome was reported in an infant whose mother had received Eritrocin, ethisterone, and ethinyl estradiol at approximately 4 weeks gestation. Eritrocin has been used prior to delivery in women colonized with group B beta-hemolytic streptococcus to reduce infant colonization. No adverse events in the infants have been reported. Eritrocin has also been used to treat genital Mycoplasma infection during the first trimester without evidence of fetal adverse effects. Pregnant women receiving Eritrocin may be more prone to hepatotoxicity. In one study of women receiving Eritrocin between the 22nd and 32nd week of pregnancy, 10% showed abnormal levels of SGOT.
Eritrocin has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. The Centers for Disease Control and Prevention considers Eritrocin the drug of choice for treatment of Chlamydia infections in pregnant women. However, Eritrocin is considered contraindicated because of drug-related hepatotoxicity. Eritrocin should only be given during pregnancy when need has been clearly established.
See references
Eritrocin is excreted into human milk in small amounts. Eritrocin is considered compatible with breast-feeding by the American Academy of Pediatrics.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|